Last reviewed · How we verify
ETICOVO (ETANERCEPT-YKRO)
ETICOVO (generic name: ETANERCEPT-YKRO) is a drug developed by SAMSUNG BIOEPIS CO LTD. It is currently FDA-approved.
At a glance
| Generic name | ETANERCEPT-YKRO |
|---|---|
| Sponsor | SAMSUNG BIOEPIS CO LTD |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ETICOVO CI brief — competitive landscape report
- ETICOVO updates RSS · CI watch RSS
- SAMSUNG BIOEPIS CO LTD portfolio CI
Frequently asked questions about ETICOVO
What is ETICOVO?
ETICOVO (ETANERCEPT-YKRO) is a pharmaceutical drug developed by SAMSUNG BIOEPIS CO LTD.
Who makes ETICOVO?
ETICOVO is developed and marketed by SAMSUNG BIOEPIS CO LTD (see full SAMSUNG BIOEPIS CO LTD pipeline at /company/samsung-bioepis).
What is the generic name of ETICOVO?
ETANERCEPT-YKRO is the generic (nonproprietary) name of ETICOVO.
What development phase is ETICOVO in?
ETICOVO is FDA-approved (marketed).
Related
- Manufacturer: SAMSUNG BIOEPIS CO LTD — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing